Canaccord lowered the firm's price target on Clover Health to $3.20 from $3.70 and keeps a Buy rating on the shares. The firm said Clover took some lumps in 2025 alongside the rest of managed care with heightened medical costs, but the company closed out the year on a solid note without further deterioration. Heading into 2026, the company has strong tailwinds, namely being paid as a 4-star plan and favorable 2026 rates from CMS. In their view, the story is plausible and compelling.
